The aim of this paper was to define the clinical characteristics of spinal ependymomas associated with neurofibromatosis Type 2 (NF2).
The authors retrospectively reviewed the clinical records of patients with NF2 who had imaging findings consistent with ependymomas and were seen at Massachusetts General Hospital between 1994 and 2007. Clinical characteristics of these patients were obtained from hospital records, imaging studies, surgical reports, and pathology reports. Mutational analysis of the NF2 gene was performed in 37 of 44 unrelated patients.
Fifty-five patients met inclusion criteria for the study. The median age at diagnosis of NF2 was 21 years; the median time after diagnosis until identification of ependymomas was 5 years. Multiple ependymomas were present in 58% of patients. The most common site of involvement was the cervical cord or cervicomedullary junction (86% of imaging studies), followed by the thoracic and lumbar cords (62% and 8%, respectively). The majority of patients had no symptoms related to their tumors (42 patients [76%]). After a median follow-up of 50 months, surgery was performed in 11 patients (20%) for symptomatic progression (indications for surgery). Mutational analysis of the NF2 gene detected alterations in 28 (76%) of 37 unrelated patients, with nonsense and frameshift mutations accounting for 64% of detected mutations. The high rate of truncating mutations may help explain the high tumor burden in these patients.
Neurofibromatosis Type 2–related ependymomas exhibit an indolent growth pattern with tumor progression limited to a minority of patients. The authors believe that surveillance is reasonable for asymptomatic ependymomas, including those with cystic areas that expand the cord. For symptomatic tumors, resection may be warranted depending on age, overall clinical status, and ease of resectability.
Abbreviations used in this paper: CMJ = cervicomedullary junction; NF2 = neurofibromatosis Type 2.
BaserME, , KuramotoL, , JoeH, , FriedmanJM, , WallaceAJ, & GillespieJE, : Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet75:231–239, 2004
BaserME, KuramotoL, JoeH, FriedmanJM, WallaceAJ, GillespieJE, : Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet75:231–239, 2004)| false
Central Brain Tumor Registry of the United States (CBTRUS): Statistical Report: Primary Brain Tumors in the United States 1998–2002(http://www.cbtrus.org/reports//2005-2006/2006report.pdf) [Accessed December 7, 2010])| false
GilhuisHJ, , van der LaakJ, , WesselingP, , BoermanRH, , BeuteG, & TeepenJL, : Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox?. J Neurooncol66:111–116, 2004
GilhuisHJ, van der LaakJ, WesselingP, BoermanRH, BeuteG, TeepenJL, : Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox?. J Neurooncol66:111–116, 2004)| false
MautnerVF, , TatagibaM, , LindenauM, , FünstererC, , PulstSM, & BaserME, : Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol165:951–955, 1995
MautnerVF, TatagibaM, LindenauM, FünstererC, PulstSM, BaserME, : Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol165:951–955, 1995)| false